AIMS: To develop a method that prospectively assesses adherence rates in paediatric patients with acute lymphoblastic leukaemia (ALL) who are receiving the oral thiopurine treatment 6-mercaptopurine (6-MP). METHODS: A total of 19 paediatric patients with ALL who were receiving 6-MP therapy were enrolled in this study. A new objective tool (hierarchical cluster analysis of drug metabolite concentrations) was explored as a novel approach to assess non-adherence to oral thiopurines, in combination with other objective measures (the pattern of variability in 6-thioguanine nucleotide erythrocyte concentrations and 6-thiouric acid plasma levels) and the subjective measure of self-reported adherence questionnaire. RESULTS: Parents of five ALL patients (26.3%) reported at least one aspect of non-adherence, with the majority (80%) citing "carelessness at times about taking medication" as the primary reason for non-adherence followed by "forgetting to take the medication" (60%). Of these patients, three (15.8%) were considered non-adherent to medication according to the self-reported adherence questionnaire (scored > or = 2). Four ALL patients (21.1%) had metabolite profiles indicative of non-adherence (persistently low levels of metabolites and/or metabolite levels clustered variably with time). Out of these four patients, two (50%) admitted non-adherence to therapy. Overall, when both methods were combined, five patients (26.3%) were considered non-adherent to medication, with higher age representing a risk factor for non-adherence (P < 0.05). CONCLUSIONS: The present study explored various ways to assess adherence rates to thiopurine medication in ALL patients and highlighted the importance of combining both objective and subjective measures as a better way to assess adherence to oral thiopurines.
AIMS: To develop a method that prospectively assesses adherence rates in paediatric patients with acute lymphoblastic leukaemia (ALL) who are receiving the oral thiopurine treatment 6-mercaptopurine (6-MP). METHODS: A total of 19 paediatric patients with ALL who were receiving 6-MP therapy were enrolled in this study. A new objective tool (hierarchical cluster analysis of drug metabolite concentrations) was explored as a novel approach to assess non-adherence to oral thiopurines, in combination with other objective measures (the pattern of variability in 6-thioguanine nucleotide erythrocyte concentrations and 6-thiouric acid plasma levels) and the subjective measure of self-reported adherence questionnaire. RESULTS: Parents of five ALL patients (26.3%) reported at least one aspect of non-adherence, with the majority (80%) citing "carelessness at times about taking medication" as the primary reason for non-adherence followed by "forgetting to take the medication" (60%). Of these patients, three (15.8%) were considered non-adherent to medication according to the self-reported adherence questionnaire (scored > or = 2). Four ALL patients (21.1%) had metabolite profiles indicative of non-adherence (persistently low levels of metabolites and/or metabolite levels clustered variably with time). Out of these four patients, two (50%) admitted non-adherence to therapy. Overall, when both methods were combined, five patients (26.3%) were considered non-adherent to medication, with higher age representing a risk factor for non-adherence (P < 0.05). CONCLUSIONS: The present study explored various ways to assess adherence rates to thiopurine medication in ALL patients and highlighted the importance of combining both objective and subjective measures as a better way to assess adherence to oral thiopurines.
Authors: Fatoumata Traore; Mary Ann O'Riordan; Carolyn Myers; Karen Groth; Ahna Hoff; Anne Angiolillo; Susan Rheingold; Dennis Drotar; Eric Kodish Journal: Pediatr Blood Cancer Date: 2006-02 Impact factor: 3.167
Authors: Karin Dilger; Elke Schaeffeler; Milan Lukas; Ulrike Strauch; Hans Herfarth; Ralph Müller; Matthias Schwab Journal: Ther Drug Monit Date: 2007-02 Impact factor: 3.681
Authors: Ahmed F Hawwa; Jeff S Millership; Paul S Collier; Koen Vandenbroeck; Anthony McCarthy; Sid Dempsey; Carole Cairns; John Collins; Colin Rodgers; James C McElnay Journal: Br J Clin Pharmacol Date: 2008-06-28 Impact factor: 4.335
Authors: Ahmed F Hawwa; Paul S Collier; Jeff S Millership; Anthony McCarthy; Sid Dempsey; Carole Cairns; James C McElnay Journal: Br J Clin Pharmacol Date: 2008-09-23 Impact factor: 4.335
Authors: Dawn L Hershman; Jennifer Tsui; Jay Meyer; Sherry Glied; Grace Clarke Hillyer; Jason D Wright; Alfred I Neugut Journal: J Natl Cancer Inst Date: 2014-10-27 Impact factor: 13.506
Authors: Alfred I Neugut; Milayna Subar; Elizabeth Ty Wilde; Scott Stratton; Corey H Brouse; Grace Clarke Hillyer; Victor R Grann; Dawn L Hershman Journal: J Clin Oncol Date: 2011-05-23 Impact factor: 44.544
Authors: Dawn L Hershman; Jennifer Tsui; Jason D Wright; Ellie J Coromilas; Wei Yann Tsai; Alfred I Neugut Journal: J Clin Oncol Date: 2015-02-17 Impact factor: 44.544
Authors: Mervat Alsous; Rana Abu Farha; Eman Alefishat; Suha Al Omar; Deema Momani; Alia Gharabli; James McElnay; Robert Horne; Rawad Rihani Journal: PLoS One Date: 2017-09-06 Impact factor: 3.240
Authors: Ahmed F Hawwa; AbdelQader AlBawab; Madeleine Rooney; Lucy R Wedderburn; Michael W Beresford; James C McElnay Journal: Arthritis Res Ther Date: 2015-10-22 Impact factor: 5.156
Authors: Caitlin J Cain; Andrea R Meisman; Kirstin Drucker; Evrosina I Isaac; Tanvi Verma; Jordyn Griffin; Jennifer M Rohan Journal: Int J Environ Res Public Health Date: 2020-03-17 Impact factor: 3.390